Physician profile
Kelliann Rawlinson
NPI 1760702666
$1,112.58
in general payments reported to CMS, 2019-2025
12 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $190 · 2023: $389 · 2024: $395 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $236.01 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $162.91 | 2023-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $155.85 | 2022-2024 | Zepbound, Mounjaro |
| Johnson & Johnson Surgical Vision, INC. | $139.40 | 2025 | Tecnis Iol, Tecnis Iol |
| Novo Nordisk INC | $125.11 | 2022-2024 | Rybelsus, Wegovy, Ozempic |
| Astellas Pharma US INC | $84.80 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $82.08 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $65.39 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.33 | 2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $14.77 | 2022 | |
| Philips North America LLC | $13.50 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.43 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelliann Rawlinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.